Trials / Completed
CompletedNCT00678392
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 723 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Axitinib (AG-013736) | axitinib will be given at a starting dose of 5 mg twice daily \[BID\] with continuous dosing |
| DRUG | Sorafenib | sorafenib will be given at a dose of 400 mg twice daily \[BID\] with continuous dosing |
Timeline
- Start date
- 2008-09-03
- Primary completion
- 2010-08-31
- Completion
- 2016-02-25
- First posted
- 2008-05-15
- Last updated
- 2019-01-09
- Results posted
- 2012-03-27
Locations
294 sites across 22 countries: United States, Australia, Austria, Brazil, Canada, China, France, Germany, Greece, India, Ireland, Italy, Japan, Poland, Russia, Singapore, Slovakia, South Korea, Spain, Sweden, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00678392. Inclusion in this directory is not an endorsement.